Cette liste est basée sur les listes de surveillance des personnes sur Stock Events qui suivent MIRM. Il ne s'agit pas d'une recommandation d'investissement.
Sur la base de 10 notations au cours des 6 derniers mois. Il ne s'agit pas d'une recommandation d'investissement.
Acheter
90%
Détenir
10%
Vendre
0%
À propos de nous
Health Technology
Pharmaceuticals: Major
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.